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Abstract
Recent clinical findings support the notion that the progressive deterioration of cholesterol homeostasis is a central player
in Alzheimer’s disease (AD). Epidemiological studies suggest that high midlife plasma total cholesterol levels are associated
with an increased risk of AD. This paper reports the plasma cholesterol concentrations, cognitive performance, locomotor
activity and neuropathological signs in a murine model (transgenic mice expressing apoB100 but knockout for the LDL
receptor [LDLR]) of human familial hypercholesterolaemia (FH). From birth, these animals have markedly elevated LDL-
cholesterol and apolipoprotein B100 (apoB100) levels. These transgenic mice were confirmed to have higher plasma
cholesterol concentrations than wild-type mice, an effect potentiated by aging. Further, 3-month-old transgenic mice
showed cholesterol (total and fractions) concentrations considerably higher than those of 18-month-old wild-type mice. The
hypercholesterolaemia of the transgenic mice was associated with a clear locomotor deficit (as determined by rotarod, grip
strength and open field testing) and impairment of the episodic-like memory (determined by the integrated memory test).
This decline in locomotor activity and cognitive status was associated with neuritic dystrophy and/or the disorganization of
the neuronal microtubule network, plus an increase in astrogliosis and lipid peroxidation in the brain regions associated
with AD, such as the motor and lateral entorhinal cortex, the amygdaloid basal nucleus, and the hippocampus. Aortic
atherosclerotic lesions were positively correlated with age, although potentiated by the transgenic genotype, while cerebral
b-amyloidosis was positively correlated with genetic background rather than with age. These findings confirm
hypercholesterolaemia as a key biomarker for monitoring mild cognitive impairment, and shows these transgenic mice
can be used as a model for cognitive and psycho-motor decline.
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Introduction
In recent years, converging lines of clinical and pathological
evidence have indicated a relationship to exist between the
deterioration of brain cholesterol homeostasis and the pathophys-
iology of sporadic AD. Epidemiological studies have shown that
hypercholesterolaemia is an early (rather than a late) risk factor for
AD, and that elevated plasma concentrations of LDL cholesterol
correlate well with the appearance of AD [1,2,3,4]. Patients with
familial hypercholesterolaemia (FH) show a particularly high
incidence of mild cognitive impairment (MCI), a prodromal stage
of abnormal cognitive performance which precedes AD [2,4].
Patients with FH provide a unique window into the role of
cholesterol metabolism in cognition. FH is caused by inherited
genetic abnormalities that directly or indirectly affect the function
of the LDL receptors (LDLRs) [5]. The LDLR family has also
been implicated in the breakdown of synaptic function in AD [6].
A number of authors have analysed the effect of hypercholes-
terolaemia in animals in terms of Ab modulation, reporting it
linked to the appearance of Ab deposits in the brains of rabbits
[7,8] and the acceleration of cerebral Ab deposition in APP-
transgenic mice [9,10]. Although it is clear that dietary and
pharmacological alterations of plasma lipid metabolism can
influence cognitive impairment and Ab deposition in AD
transgenic animals, it is not yet known whether increases in
baseline lipid profiles in non-AD mouse models provoke
behavioural deficits or neurodegeneration. Some authors have
reported the absence of LDLRs in 6 month-old mice to lead to
impaired spatial memory [11], although no aging studies nor
cholesterol determinations were undertaken. Other authors report
transgenic LDLR-deficient Tg2576 mice to develop high-level
hypercholesterolaemia and age-dependent cerebral b-amyloidosis
[12]. However, both Tg2576 and LDLR-deficient Tg2576 mice
showed impaired learning after Ab deposition, although the latter
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unclear whether APP overexpression and/or hypercholesterolae-
mia truly contribute to cognitive impairment. Moreover, some
authors report that plasma cholesterol levels are not significantly
altered in classic murine AD models [9] such as Tg-CRND8,
APP/PS1 or Tg-SwDI/B, suggesting that these transgenic mice do
not replicate the hypercholesterolaemia observed in humans. If
hypercholesterolaemia really is a risk factor for cognitive
impairment, the optimal animal model in which to study this
would be one in which hypercholesterolaemia appears early in life.
The apoB100/LDLR-/- mouse developed by Powell-Braxton
et al. [13] mimics FH very well since the hypercholesterolaemia
these animals suffer is caused almost entirely by high plasma
concentrations of cholesterol-rich apoB100-containing LDL, i.e.,
the same as that which typically occurs in humans. To test whether
hypercholesterolaemia facilitates the progress of MCI to AD, the
plasma cholesterol levels, cognitive and locomotor status, and the
pathological signs of such progress were monitored in naı ¨ve
apoB100/LDLR-/- mice at 3 and 18 months of age. The results
suggest that hypercholesterolaemia may be an important factor
influencing the neuropathological changes and cognitive and
psychomotor impairment associated with aging.
Materials and Methods
A) Animals
Ethics statement. All experiments were undertaken in
accordance with the guidelines of the European Union, took
place under the supervision of veterinary staff, and were approved
by the ethical committees of NEURON BPh (‘‘Comite ´E ´tico de
Bienestar Animal’’ or CEBA) and the University of Granada
(‘‘Comite ´E ´tico de Experimentacio ´n Animal’’ or CEEA). The
approval number of the CEEA was Ref. CEEA 133-2007.
Additionally, although the Spanish Law does not require it,
NEURON BPh evaluated the experimental use of animals and the
particular procedures through its ethical committee (CEBA).
Experimental procedures. The study animals were 3- and
18-month-old, male, homozygous apoB100/LDLR-/- transgenic
mice and male, wild-type C57Bl/6 mice (Charles River,
Barcelona, Spain). Male mice were selected because they show
higher levels of total and LDL-cholesterol than females [13]. All
were housed in an air-conditioned room under a 12L/12D
photoperiod until sacrifice, and had free access to water and food.
At the moment of sacrifice the mice were deeply anaesthetized
with fluorane (2% with O2 at 0.2 L/min and air at 1.5 L/min)
and blood collected in EDTA-coated tubes following cardiac
puncture. The plasma obtained was conserved at 280uC for
biochemical determinations. Immediately after blood extraction
the animals were perfused intracardially with PBS followed by
3.7% formaldehyde in phosphate buffer. Their brains and aortas
were then removed and post-fixed in 3.7% formaldehyde in
phosphate buffer.
B) Plasma cholesterol determinations
Plasma total cholesterol (TC), LDL-cholesterol, HDL-choles-
terol, triglycerides (TG) and apoB were measured spectrophoto-
metrically using kits from Biosystems (Barcelona, Spain). Free (FC)
and esterified (EC) cholesterol were determined fluorometrically.
Briefly, plasma samples were diluted 1/500 in a sodium phosphate
monobasic buffer with 0.5% triton X-100 (pH 7). Cholesterol in
the concentration range 0.31 to 20 mg/mL was transferred to 96-
well plates to produce a fluorometric standard curve; 25 mL of the
diluted plasma were also transferred to 96-well plates for the
determination of FC. 75 mL of 2-(N-morpholino) ethanesulphonic
acid (MES) 0.05 M (pH 6.5) containing cholesterol oxidase
(0.5 U/mL), type VI horseradish peroxidase (4 U/mL) and
ampliflu red (20 mg/mL) were added to the plates and reactions
allowed to proceed for 15 min at 37uC. The fluorescence
intensities were measured using a multi-well plate reader equipped
with a filter set for excitation and emission at 530 and 580 nm
respectively (Infinite 200, Tecan) [14]. Cholesterol esterase
(0.8 U/mL) was added to the reaction mixture to measure total
cholesterol. Esterified cholesterol was calculated as the difference
between TC and FC.
C) Behaviour testing
Evaluation of muscular strength. The grip strength test
determines the muscular strength and neuromuscular integration
relating to the grasping reflex in the forepaws [15]. Grip strength
was assessed using a grip strength meter (Panlab, Barcelona). The
strength measurements of young transgenic mice (n=6), young
wild type mice (n=6), aged transgenic mice (n=8) and aged wild
type mice (n=8), were measured five times (in succession) by an
investigator blinded to genotype. The maximum grip strength
values were used for subsequent analysis; data were expressed as
force in grams normalized to body weight in kg (g/kg).
Motor coordination. Motor coordination was tested using
an accelerating rotarod LE8200 apparatus (Panlab, Barcelona). All
animals (n=7 for both aged groups of mice, and n=6 for both
young groups) were given 1 min training before testing and were
then placed on the rod and tested from 4 to 40 rpm for a
maximum of 120 s. Each animal underwent a minimum of three
trials with 10 min intervals between them, during which time the
mice were allowed to recover in their home cages. The total time
that each mouse was able to stay on the rod was recorded
automatically by a trip switch under the floor of each rotating
drum, activated by the animal’s fall. The average time to fall (fall
latency) for three trials was then determined [16].
Open field testing. The global locomotor activity of the mice
was determined by open field testing as previously described [17].
Tests were performed in an environment chamber that provided
white noise and low, indirect lighting. The animals were placed in
the centre of the 45645640 cm arena (Panlab, Barcelona) and
allowed to explore freely for 10 min. The exploration track of each
mouse (n=7 for the aged groups and n=6 in young groups) was
video-recorded. SMART software (Panlab, Barcelona) was used to
monitor spontaneous locomotor activity. Periods of immobility
were recorded after the first 2 s of a lack activity. Vertical activity
was calculated by counting the number of rearings.
Memory testing. The long-term memory for different
objects, their spatial location and their order of presentation was
assessed in a familiar open field (35645645 cm) made of red
PVC. A video camera was mounted 100 cm above the box to
record the trials on a hard disk for later analysis. Diffuse white light
provided an illumination density of approximately 3.0 lux at the
centre of the open field. Four identical examples of two objects
differing in height, colour, shape and surface texture were then
presented to the mice. After each test period, the apparatus and
objects were thoroughly cleaned with a 70% ethanol solution to
remove odour cues.
One week prior to testing, 6 mice per age/genotype group were
allowed an exploration period during which they became familiar
with the test apparatus (five sessions of 10 min each) and handling
procedure. Memory status was analysed using the integrated
memory test, following a procedure adapted from a previously
described experiment [18] that has been validated in a KA-
induced neurodegeneration mouse model [19]. Briefly, the mice
underwent two sample trials and a test trial. In the first sample trial
ApoB100/LDLR-/- Mice and Behavioural Impairment
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identical objects arranged in a triangular configuration and were
allowed to explore them for 10 min. After a delay of 50 min each
mouse received a second sample trial in which four novel objects
were presented; these were arranged in a square configuration.
The objects presented in sample trials 1 and 2 were randomly
determined for each mouse. After an additional delay of 50 min
each mouse underwent a test trial identical to the second, except
that two of the objects from sample trial 1 (‘‘old familiar’’ objects)
and two of the objects from sample trial 2 (‘‘recent familiar’’
objects) were presented. For each mouse, the time spent exploring
the object was recorded with a stopwatch. The exploration of an
object was assumed to be underway when the mouse approached
it and had physical contact with it, either with its vibrissae, snout,
or forepaws. Immobility in the vicinity of an object was considered
not to be exploratory behaviour. The total time spent exploring
the four objects during the sample and test trials was scored. The
ratio between the time spent exploring ‘‘old familiar’’ objects and
‘‘recent familiar’’ ones shows the temporal memory to be
functional if the value is higher than 1 (differences in exploration
time were considered significant when p,0.05). The ratio between
the time spent exploring displaced and unmoved ‘‘old familiar’’
shows the spatial memory to be functional if the value is higher
than 1 (differences in exploration time were considered significant
when p,0.05). All experiments were performed during the light
phase of the day.
D) Immunohistochemistry
Paraffin-embedded sections (5 mm) of aorta and brain were
deparaffinated and dehydrated for immunohistochemical label-
ling. The latter was performed by incubating the samples
overnight with each appropriately diluted primary antibody in
10% blocking solution at 4uC and then with the appropriate
biotinylated secondary antibody (1:500) (Jackson ImmunoRe-
search, Tokyo, Japan) at room temperature for 1 h. The samples
were then processed using the Elite ABC Perox kit (Vector
Laboratories, Burlingame, CA), and the peroxidase reaction
product detected using 3,39-diaminobenzidinetetrahydrochloride
(DAB) (Vector Laboratories). Finally, sections were mounted in
DPX (Panreac, Barcelona). Digital bright-field images were
captured using a Zeiss Axiovert Z1 (Carl Zeiss, Barcelona, Spain)
optical microscope equipped with a colour camera. A mouse
MAP2 monoclonal antibody (1:200) (Sigma-Aldrich, MO) was
used to detect microtubule signals [20] and a mouse HNE
monoclonal antibody (1:100) (Jaica, Fukuroi, Japan) to detect
oxidative damage by lipid peroxidation [21]. Rabbit anti-glial
fibrillary acidic protein (GFAP) polyclonal antibody (1:5000)
(Dako, Glostrup, Denmark) was used to identify the activation
and proliferation of astrocytes [22].
E) Detection of cerebral b-amyloidosis
The ACCUSTAINH Congo red staining kit (Sigma) was used to
stain amyloid deposits following the manufacturer’s instructions.
Briefly, samples were deparaffinated and hydrated with deionised
water. The slides were then stained with Mayer’s haematoxylin
solution for 10 min, rinsed in tap water for 5 min, and placed in
an alkaline sodium chloride solution for 20 min. Samples were
then stained with alkaline Congo red solution for 20 min, rinsed in
absolute ethanol, cleared in xylene, and mounted. The slides were
examined microscopically using regular light to detect amyloid
deposits, and their presence confirmed using polarized light to
check for apple-green birefringence (a characteristic of these
deposits).
For b-amyloid immunodetection, deparaffinated and dehydrat-
ed brain sections were incubated overnight with monoclonal anti-
b-amyloid (4G8) antibody (1:500) (Sigma-Aldrich, MO) in
blocking solution at 4uC and then with the appropriate
biotinylated secondary antibody (1:500) (Jackson ImmunoRe-
search, Tokyo, Japan) in PBS at room temperature for 1 h. The
samples were then processed using the Elite ABC Perox kit (Vector
Laboratories, Burlingame, CA), and the peroxidase reaction
product detected using DAB (Vector Laboratories).
F) Quantification of aortic atherosclerosis
The aortic arch was discarded and the thoracic aorta embedded
in paraffin. Sections were then cut at intervals of 5 mm. Slides from
representative areas of the artery were stained with Van Gieson
stain to assess the presence and severity of atheroma plaque and
the characteristics of the media layer. Two independent
investigators blind to the study protocol evaluated each section
for different characteristics relating to the presence or absence of
plaque and the deterioration of the elastic fibres in the media layer.
A score of 0–3 (0 perfect condition, 3 extremely deteriorated) was
awarded to each slide for 1) the elasticity or aging of fibres, 2) the
rupture of fibres, and 3) the loss of the classical structure of the
elastic fibres.
G) Statistical analysis
The mean and SEM were calculated for all ratios and
parametric values. One-way analysis of variance (ANOVA)
followed by a Newman-Keuls post-hoc test was used to compare
grip strength and rotarod data between the different age/genotype
groups. The two-tailed t test was used to compare the ratios
recorded in the integrated memory test against the preset
paradigm value of 1. The one-tailed t test was used to compare
the ratios recorded for the different genotype/age groups.
Significance was set at p,0.05. All statistical analyses were
performed using STATISTICA for Windows (Tulsa, OK).
Results
A) Plasma determinations
Figure 1 shows the results for the lipid variables in the 3 and 18-
month-old wild-type and transgenic mice. Plasma TC, FC, EC,
LDL-cholesterol, apoB and TG concentrations were significantly
higher at both 3 and 18 months of age in the transgenic mice,
particularly so for LDL-cholesterol. The transgenic mice also
showed lower plasma concentrations of the atheroprotective HDL-
cholesterol fraction at both ages. These mice therefore suffer
hypercholesterolaemia. Indeed, the young transgenic mice had
higher concentrations of TC, FC, EC, LDL and apoB (but not
HDL) than the aged wild-type mice, indicating that their genetic
background is linked to a more dramatic hypercholesterolaemia
than that seen in normal aging.
B) Analysis of overall locomotor activity
In the rotarod test, the aged transgenic mice showed
significantly shorter fall latencies than the aged wild-type mice
(p,0.05) (Fig. 2). In the grip strength test, the 3-month-old
transgenic animals showed significantly reduced grip strength
compared to the young wild-type mice (p,0.05). Aging was
involved in the loss of grip strength since both the 18-month-old
wild-type and transgenic mice showed significant reductions in the
value of this variable compared to 3-month-old wild-type mice
(p,0.05). In the analysis of global activity in the open field test, the
transgenic mice showed a severe reduction in vertical activity as
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(p,0.05).
C) Analysis of memory status
After the motor activity tests, cognitive status was assessed in the
same animals using the integrated memory test, a paradigm
previously optimised to evaluate episodic-like memory in mice
[19]. This method includes the analysis of episodic-like memory
(temporal and spatial order memory) (Fig. 2). The young wild-type
mice showed their temporal memory to be intact, returning ratios
significantly greater than the paradigm value, whereas the aged
wild-type mice showed a significant reduction in both types of
memory (p,0.05). With respect to temporal memory, both the 3-
and 18-month-old transgenic mice returned significantly lower
ratios than wild-type mice of the same ages (p,0.05). In additional
analysis, the 18-month-old transgenic mice, showed significantly
poorer spatial memory values than their 3-month-old counterparts
(p,0.05). In summary, young transgenic mice showed a temporal
memory decline similar to that seen in aged wild-type mice,
indicating that the formers’ hypercholesterolaemia is likely
involved in memory impairment. Spatial memory decline, in
contrast, appears to be more related to ageing.
D) Determination of aortic atherosclerosis
To test whether the transgenic mice were more susceptible than
wild-type mice to atherosclerosis, signs of aortic atherosclerosis
were sought in both young and aged animals. The aged wild-type
mice and the young transgenic mice showed a deterioration of the
middle layer (Fig. 3). The 18-month-old transgenic mice, however,
had evident atheroma plaques of considerable size, with vast
necrotic cores and with thin fibrous caps about to break. The high
LDL-cholesterol concentrations of these mice, acting synergisti-
cally with ageing, would therefore appear to be involved in the
development of such atherosclerosis and eventually non-stable
plaques. The severe atherosclerotic process underway might be
associated with poor brain irrigation, leading to impaired cognitive
function. Interestingly, neither the young transgenic nor wild-type
animals showed any significant aortic atherosclerotic lesions.
Aortas showing deterioration of the elastic fibres (mainly the loss
of their classic structure and rupture) were much more commonly
seen in 18-month-old transgenic mice (overall mean score
1.560.3). The young transgenic mouse aortas showed a marked
alteration of the classical structure (overall mean score 0.660.2),
while in the 18-month-old wild-type mice the fibres showed a loss
of elasticity and their clear aging (total score, 0.960.3). The
Figure 1. Values of plasma variables in young and aged wild-type and transgenic mice. Total cholesterol, HDL-cholesterol, LDL-
cholesterol, apoB and triglycerides were assessed by spectrophotometric methods (blue bar = wild-type, red bar = transgenic). Free and esterified
cholesterol were determined by fluorometric assays. The results, expressed in mg/dL, are means6SEM (n$6 per group). *Significantly different
(P,0.05) compared to 3-month-old wild-type mice;
#Significantly different (P,0.05) between wild type and transgenic mice.
doi:10.1371/journal.pone.0022712.g001
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score 0.060.0).
E) Neuropathology
Neuritic dystrophy. MAP2 monoclonal antibodies were
used to determine the degree of neuritic dystrophy as a marker
of neuronal damage (Fig. 4). Compared to the wild type mice of
the same age, the dendrites and axons in the lateral entorhinal
cortex and amygdaloidal basal nucleus of the 3-month-old and 18-
month-old transgenic mice showed a clear reduction in the MAP2
signal. However, no difference was seen between the transgenic
mice of either age. Thus, staining is genotype and not age-
dependent. No loss of the MAP2 stain was observed in the 3-
month-old or 18-month-old wild-type mice, whose microtubule
networks showed dense and uniform labelling. However, the
dentate gyrus of the hippocampus of the 18-month-old wild-type
mice showed a strong reduction in dendrite – but not axon -
MAP2 staining compared to the young wild-type mice. This
pattern of reduction in dendrite MAP2 staining was also observed
in both the young and aged transgenic mice. These results suggest
that the transgenic genotype causes the deterioration of the
hippocampus, a very important area involved in memory.
Oxidative damage. Staining of the HNE-conjugated
proteins were used to study the degree of lipid peroxidation (a
marker of oxidative damage) in the brain. A large number of
deeply stained neurons were seen in various brain regions in the
transgenic mice. Staining was stronger in the hippocampus and
amygdala of the 18-month-old transgenic mice than in the 3-
month-old transgenic mice (Fig. 5). Very few isolated neurons were
stained in the brains of wild-type mice. These results show the
strong relationship between the transgenic genotype and oxidative
damage in the brain; no such clear relationship is seen with ageing.
Astrogliosis. Brain samples were examined for signs of
astrogliosis using GFAP polyclonal antibodies (Fig. 6). The 18-
month-old wild type mice showed more activated astrocytes than
the 3-month-old wild type mice. Astrogliosis was detected in the
neuropil of the hippocampus and in several regions of the cortex
and amygdala. These findings relate an increase in astrogliosis to
ageing. Both the young and aged transgenic mice showed an
Figure 2. Behavioural phenotyping. Effects of genotype (blue bar = wild-type, red bar = transgenic) and age on fall latency (in seconds to fall
from the accelerating rotarod); grip strength (expressed as g/kg of weight); vertical activity (number of rearings) and period of immobility (in seconds,
open field test); and temporal memory (as a ratio) and spatial memory (as a ratio). Data are expressed as means6SEM. *Significantly different
(P,0.05) compared to 3-month-old wild-type mice;
#Significantly different (P,0.05) between wild type and transgenic mice.
doi:10.1371/journal.pone.0022712.g002
Figure 3. Structure of the thoracic aorta of young and aged
wild-type and transgenic mice. Six sections (stained with Van
Gieson stain) from different areas of the aorta were evaluated by two
blinded observers, scoring for the deterioration of the elastic fibres in
the media layer. The absence or presence of atheroma plaque was also
independently examined. Scale bar: 100 mm.
doi:10.1371/journal.pone.0022712.g003
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22712Figure 4. MAP2 staining in young and aged wild-type and transgenic mice. MAP2 staining of coronal sections (1.78 mm from the bregma)
of the left (contralateral) hemisphere of a mouse brain from each of the age/genotype groups. Hippocampus and three areas of the cortex showing
several nuclei of the temporal lobe cortex, such as the lateral entorhinal, ectorhinal, perirhinal and temporal-association cortices, the primary and
secondary somatosensory cortices, lateral parietal association cortex and visual cortex, and the cortical amygdaloidal nucleus and
amygdalohippocampal area. Scale bar: 25 mm.
doi:10.1371/journal.pone.0022712.g004
Figure 5. Lipid peroxidation in young and aged wild-type and transgenic mice. HNE stains of coronal sections (1.68 mm from bregma) of
the left (contralateral) hemisphere of a mouse brain from each of the age/genotype different groups. The hippocampus and three areas of the cortex
are represented, showing several nuclei of the temporal lobe cortex, such as the lateral entorhinal, the ectorhinal, perirhinal and temporal-association
cortices, the primary and secondary somatosensory cortices, the lateral parietal association cortex and visual cortex, and the cortical amygdaloidal
nucleus and amygdalohippocampal area. Scale bar: 25 mm.
doi:10.1371/journal.pone.0022712.g005
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entorhinal and motor-sensorial area of the cortex, and in the basal
amygdaloidal nucleus.
Cerebral b-amyloidosis. Ab deposits appeared mostly as
apple-green birefringent amyloid deposits restricted to the vessel
walls (Fig. 7). Congo red staining revealed age-dependent cerebral
b-amyloidosis in wild-type mice: no Ab immunoreactive deposits
were detected in the young mice, but were detected in the aged
mice, mainly in the hypothalamus and occasionally in cortical
areas (Fig. 7). However, in the young transgenic mice, Ab deposits
were detected in the vessel walls similar to those found in the aged
wild-type mice. After 18 months, the Ab deposits in the
hypothalamus and cortical areas increased significantly in
number and birefringence intensity in the transgenic mice (Fig. 7).
To definitely confirm the Ab deposits in the vessel walls, an
immunohistochemical analysis using the monoclonal 4G8 anti-
body was performed (Fig. 8). Again, cerebral b-amyloidosis was
dependent on genotype and age. Ab immunoreactive deposits
were not detected in the young wild-type mice. On the contrary,
young transgenic mice presented specific Ab deposits in the vessel
walls, and the signal intensities were clearly increased in aged wild-
type and transgenic mice.
Discussion
Clinical and epidemiological evidence suggest that individuals
with elevated midlife plasma cholesterol are at increased risk of
dementia and AD [1,2,3,4]. However, while much attention has
been focused on the effect of cholesterol in murine AD models,
little attention has been paid to neurodegeneration in hypercho-
lesterolaemic mice; most studies have focused on the accumulation
of amyloid plaques [7,8,9]. It remains unclear whether plasma
cholesterol levels increase the risk of AD via the transport of
cholesterol into the brain, or via indirect mechanisms such as an
increase in cholesterol metabolites which then enter the brain.
Either may be able to trigger Ab production [23], and therefore
cerebrovascular disease [24]. To investigate this, the present study
Figure 6. Astrogliosis in young and aged wild-type and transgenic mice. GFAP staining of coronal sections (1.58 mm from bregma) of the
left (contralateral) hemisphere of a mouse brain from each of the age/genotype different groups. The hippocampus and three areas of the cortex are
represented, showing several nuclei of the temporal lobe cortex, such as the lateral entorhinal, ectorhinal, the perirhinal and temporal-association
cortices, the primary and secondary somatosensory cortices, the lateral parietal association cortex and visual cortex, and the cortical amygdaloidal
nucleus and amygdalohippocampal area. Scale bar: 100 mm.
doi:10.1371/journal.pone.0022712.g006
Figure 7. b-amyloidosis in the cerebral vessels of young and
aged wild-type and transgenic mice. Congo red staining of coronal
sections from each of the age/genotype different groups (1.62 mm
from bregma). b-amyloid deposition can be seen in a vessel wall viewed
under regular and polarized light (insets); note the apple-green
birefringence specific to amyloid. Scale bars: 11 mm.
doi:10.1371/journal.pone.0022712.g007
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concentration along with the neuropathological and cognitive
and psychomotor alterations in a hypercholesterolaemic mouse
model (apoB100/LDLR-/-) that mimics human FH [13].
The main finding of this work was the direct association
between FH and behavioural impairment in young hypercholes-
terolaemic mice. These results are in line with those of
epidemiological studies showing that the proportion of patients
with FH showing abnormal cognitive function and meeting the
criteria for MCI is significantly higher than in controls [4]. Patients
with FH are exposed to higher cholesterol levels from birth, and it
is reported that hypercholesterolaemia may be an early risk factor
for AD [2,4]. Moreover, in patients with FH, it is very common for
the LDLRs that participate in synapse maintenance to be
dysfunctional, a pathogenic sign of AD [6]. Over 600 mutations
causing FH in humans have been identified [25], and several
polymorphisms in the LDLR gene have been associated with AD
[26]; the potential progress from MCI to AD in people with these
genetic backgrounds should be monitored.
The transgenic mice used in the present study are characterized
by their deficiency in LDLRs and in their inability to splice apoB
mRNA. This results in markedly elevated LDL cholesterol and
apoB100 levels (thus providing a model of human FH) that develop
extensive atherosclerosis when fed a chow diet [13]. This model is
superior to previous hypercholesterolaemic models in which mice
were only deficient in LDLRs, that had only mildly elevated LDL
cholesterol levels and little atherosclerosis [27], or that were based
exclusively on the overexpression of apoB100 and no alteration in
plasma total cholesterol [28]. It should be noted that, in the present
work, the transgenic mice were subjected to no pharmacological
treatmentorhypercholesterolaemicdiet.With respecttomostofthe
variables analysed, the young mice showed profiles similar to those
of aged normal old mice, indicating that the hypercholesterolaemia
of the former simulates accelerated aging and induces cognitive and
psychomotor impairment. Independent of age the transgenic mice
had high plasma TG, TC, FC and EC concentrations. Moreover,
the plasma LDL-cholesterol fraction was dramatically increased
compared to the control mice, as was apoB production, while the
plasma HDL-cholesterol concentration was much lower.
An inverse relationship has been reported between plasma
HDL-cholesterol and cerebral b-amyloid load in Tg2576 mice fed
an atherogenic diet [10], and it has been shown that HDL-
cholesterol increases the degradation of Ab by microglia in vitro
[29]. Additionally, the elevation of plasma TG precedes amyloid
deposition in the murine Tg-CRND8, APP/PS1 and Tg-SwDI/B
AD models [30]. In AD patients, LDL-cholesterol and apoB
concentrations are increased, and correlate with brain Ab
concentrations [31,32,33]. In general, elevated TC, LDL and
TG characterise the lipid profiles of AD subjects, while high HDL-
cholesterol levels in elderly individuals are associated with a
reduced risk of the disease [34,35,36,37]. These results in AD-
mouse models and AD patients are highly coincident with the
findings in the present transgenic mice, and together indicate that
changes in the plasma cholesterol profile might be involved in the
initiation and progress of the neurodegenerative process. More-
over, since the increase in TC, FC, EC, LDL, apoB and TG, plus
the reduction in HDL-cholesterol, are predictors of cognitive
impairment, they might be proposed as translational biomarkers
for MCI and/or AD.
The behavioural deficits observed in the aged wild-type and
young and old transgenic mice correlated well with their high
plasma cholesterol concentrations. Young transgenic mice showed
a loss of muscle strength compared to the young wild-type mice.
Moreover both the young and old transgenic mice showed longer
periods of immobility and fewer rearings than wild-type mice in
the open field test. This indicates that global motor activity is
compromised as a consequence of hypercholesterolaemia. These
results are in line with the observed decline in strength in older
people – which is also associated with an increased risk of AD [38].
At 18 months of age, both genotypes experienced significant
temporal and spatial memory deficits. However, the young
transgenic mice also showed a significant decline in temporal
memory (compared to young wild-type mice), indicating that these
animals suffer an MCI-like condition. These results are in line with
those recorded in humans with vascular risk factors for AD [39,40]
and with the cognitive impairment that characterizes the clinical
progression of AD.
The present results relating to hypercholesterolaemia and
cognitive and psychomotor impairments are in line with those of
previous reports indicating cholesterol-induced memory deficits in
transgenic mice expressing human mutant APP [41], with those of
studies on hypercholesterolaemia-induced memory dysfunction in
LDLR-/- mice [11,33], and with those on cognitive impairment in
rats fed high saturated fat diets [42]. However, the effect of the
aging, which is critical in the context of neurodegenerative
diseases, was not taken into account in these earlier studies.
Neuropathological analyses were undertaken to study the
potential correlation between cognitive and psychomotor impair-
ment and the status of different brain areas. Different signs of
chronic neuronal damage were recorded in the 3-month-old
transgenic mice, including neuritic dystrophy, oxidative damage
and astrogliosis. The presence of neuronal damage in the
entorhinal cortex and the basal amygdaloid nucleus in these
young mice explains the impairment detected in their temporal
memory. In addition, clear signs of oxidative damage were
detected in the neurons of the sensory-motor cortex of the young
transgenic mice, which explains the accelerated motor and
coordination impairment in them. In the hippocampus, however,
astrogliosis and oxidative damage was more dependent on age
than genotype.
To relate the potential involvement of atherosclerosis and
cerebrovascular damage to the behavioural and neuropathological
changes observed in the transgenic mice, the aorta was examined
Figure 8. Ab immunodetection in the cerebral vessels of young
and aged wild-type and transgenic mice. Immunohistochemistry
against Ab of coronal sections from each of the age/genotype different
groups. Scale bar: 11 mm.
doi:10.1371/journal.pone.0022712.g008
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amyloidosis. Atherosclerosis has been associated with AD and
cerebral angiopathy in humans [43,44], and recent findings
indicate that vascular risk factors and neurovascular dysfunction
play integral roles in the pathogenesis of AD [45]. Moreover, a
relationship is reported between aortic atherosclerosis and brain
Ab deposits and learning deficits in transgenic Tg2576 mice fed an
atherogenic diet [41]. Cholesterol may affect b-amyloidosis by
modulating the proteolytic processing of APP and/or subsequent
amyloid formation and deposition [9,46]. In humans, Ab peptide
accumulates in the core of senile plaques and in blood vessel walls;
in fact, .90% of human amyloid plaques are in direct contact
with capillaries [47]. Moreover, it has been shown that cerebral
amyloid angiopathy (CAA) caused by Ab deposition has a
pathogenic role in dementia (reviewed in [48]). Indeed, many of
the mouse models for genetic AD that harbour different human
APP mutations have also been shown to exhibit CAA [49,50],
although the overexpression of APP alone causes no Ab deposition
in most mouse lines [51], and mouse app does not generate
amyloid plaques. Interestingly, the present transgenic mice showed
early cerebrovascular b-amyloidosis that was exacerbated with
age, in the same way that, in human mutant APP mouse models, a
close relationship is seen between high plasma cholesterol and
brain vessel amyloidosis [49,50]. In the present transgenic mice,
the severity of the cognitive and psychomotor deficits were closely
associated with an increase in amyloidosis, suggesting that
exacerbation of this event, rather than atherosclerosis, may be a
potential mechanism for its detrimental effect on motor activity
and memory. The elevated cholesterol concentrations of the
transgenic mice may induce damage in the brain vasculature via
the deposition of Ab in the blood vessels. The eventual obliteration
of lumens [52] would lead to the dysfunction of the affected areas.
Certainly, increased plasma cholesterol concentrations correlate
with increased Ab accumulation in human brains [53].
In summary, hypercholesterolaemia early in the life of the
ApoB100/LDLR-/- mice is associated with neuritic dystrophy,
oxidative damage, astrogliosis and vascular b-amyloidosis, leading
to neuronal damage and eventually psychomotor and cognitive
impairment. The present results suggest that changes in plasma
lipid homeostasis precede cognitive and psychomotor decline, and
potentiate the cerebral b-amyloidosis that occurs with aging.
These transgenic mice could provide an excellent model for the
study of sporadic AD in humans.
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